LDL-C Goal Achievement After Adding or Switching to Ezetimibe in Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable HeFH
Comparative Risk of Transfusion and Incremental Total Hospitalization Cost for Primary Unilateral, Bilateral, and Revision Total Knee Arthroplasty Procedures
Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure
Comparing Instant Health Data and SAS for Evaluation of Incidence Rates in Multiple Sclerosis Using MarketScan
Bleeding Risk for Non-Valvular AF Patients Prescribed Warfarin, or Standard Doses of Apixaban 5mg BID, Dabigatran 150mg BID or Rivaroxaban 20mg QD in Real-World Practice: Findings From EHR
Lead Damage in the First-Year Following Cardiac Implantable Electronic Device (CIED) Replacement: Incidence and Costs Based on Device Type
Real-World Bleeding Risk among Non-Valvular Atrial Fibrillation (NVAF) Patients Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin: Analysis of Electronic Health Records
Clinical and Demographic Characteristics According to Dosage among Non-Valvular Atrial Fibrillation Patients Newly Initiated on Novel Oral Anticoagulants
Characteristics of Patients Initiating Oral Anticoagulant Therapy for Management of Non-Valvular Atrial Fibrillation (NVAF)